Palbociclib Alternatives Compared
| Palbociclib | Verzenio (abemaciclib) | Keytruda (pembrolizumab) |
|
|---|
| Palbociclib | Verzenio (abemaciclib) | Keytruda (pembrolizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer, Liposarcoma, Breast Cancer - Male. Palbociclib may also be used for purposes not listed in this medication guide. |
Prescription only
Verzenio (abemaciclib) is a targeted treatment that helps to reduce the growth and spread of cancer cells in the body. It may be used to treat HR+ HER2-, node-positive, early breast cancer at high... View more |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Related suggestions Breast Cancer
|
|||||||||||||||
| More about Palbociclib | More about Verzenio (abemaciclib) | More about Keytruda (pembrolizumab) | ||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||
|
Palbociclib has an average rating of 6.9 out of 10 from a total of 100 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 28% reported a negative effect. |
Verzenio has an average rating of 8.2 out of 10 from a total of 25 ratings on Drugs.com. 64% of reviewers reported a positive effect, while 4% reported a negative effect. |
Keytruda has an average rating of 4.8 out of 10 from a total of 241 ratings on Drugs.com. 39% of reviewers reported a positive effect, while 51% reported a negative effect. |
||||||||||||||||
| Drug Class | ||||||||||||||||||
| Side Effects | ||||||||||||||||||
| Generic Availability | ||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Verzenio prices |
View all Keytruda prices |
||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||
|
N/A |
|
|
||||||||||||||||
| Brand Names | ||||||||||||||||||
| Ibrance |
N/A |
N/A |
||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
|
29 hours |
24.8 hours |
624 hours |
||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | ||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | ||||||||||||||||||
|
A total of 472 drugs are known to interact with Palbociclib:
|
A total of 343 drugs are known to interact with Verzenio:
|
A total of 402 drugs are known to interact with Keytruda:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | ||||||||||||||||||
| First Approval Date | ||||||||||||||||||
|
February 03, 2015 |
September 28, 2017 |
N/A |
||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||
| More Information | ||||||||||||||||||
| Patient resources | ||||||||||||||||||
| Professional Resources | ||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||
|
||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.